AttributesValues
rdf:type
rdfs:seeAlso
Description
  • Background: The aim of this randomized study was to investigate the effect of seven-day high-dose atorvastatin therapy on the incidence of peri-procedural myocardial infarction (PMI) in patients receiving long-term statin therapy. Methods: The patients with stable angina receiving statin therapy and referred for percutaneous coronary intervention (PCI) were randomized (ratio 1: 1) to a 7-day pre-treatment with atorvastatin of 80 mg daily and subsequent PCI (Atorvastatin group), or immediate PCI (Control group). The incidence of PMI was based on serum concentration of creatine kinase myocardial band (CK-MB) mass and troponin I (TnI), which were measured prior to and between 16 and 24 h post PCI. The values were considered as positive if they were elevated }= 3 times the upper limit normal. Results: We randomized 202 patients (male 67%, 65.5 +/- 9.2 years; 100 vs. 102 pts.). There were no significant differences in the baseline characteristics among the randomized groups. The incidence of PMI, based on post-interventional release of TnI and/or CK-MB mass was 15% in the Atorvastatin group vs. 14% in the Control group (p = 0.80). One patient (3%) in Atorvastatin group suffered from MI between randomization and PCI. Conclusions: These results suggest that 7-day pre-PCI therapy with high-dose atorvastatin did not reduce the occurrence of PMI in patients receiving chronic statin therapy. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
  • Background: The aim of this randomized study was to investigate the effect of seven-day high-dose atorvastatin therapy on the incidence of peri-procedural myocardial infarction (PMI) in patients receiving long-term statin therapy. Methods: The patients with stable angina receiving statin therapy and referred for percutaneous coronary intervention (PCI) were randomized (ratio 1: 1) to a 7-day pre-treatment with atorvastatin of 80 mg daily and subsequent PCI (Atorvastatin group), or immediate PCI (Control group). The incidence of PMI was based on serum concentration of creatine kinase myocardial band (CK-MB) mass and troponin I (TnI), which were measured prior to and between 16 and 24 h post PCI. The values were considered as positive if they were elevated }= 3 times the upper limit normal. Results: We randomized 202 patients (male 67%, 65.5 +/- 9.2 years; 100 vs. 102 pts.). There were no significant differences in the baseline characteristics among the randomized groups. The incidence of PMI, based on post-interventional release of TnI and/or CK-MB mass was 15% in the Atorvastatin group vs. 14% in the Control group (p = 0.80). One patient (3%) in Atorvastatin group suffered from MI between randomization and PCI. Conclusions: These results suggest that 7-day pre-PCI therapy with high-dose atorvastatin did not reduce the occurrence of PMI in patients receiving chronic statin therapy. (C) 2013 Elsevier Ireland Ltd. All rights reserved. (en)
Title
  • Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study
  • Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study (en)
skos:prefLabel
  • Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study
  • Effect of seven-day atorvastatin pretreatment on the incidence of periprocedural myocardial infarction following percutaneous coronary intervention in patients receiving long-term statin therapy. A randomized study (en)
skos:notation
  • RIV/00216208:11130/13:10209630!RIV14-MSM-11130___
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • I
http://linked.open...iv/cisloPeriodika
  • 3
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 71726
http://linked.open...ai/riv/idVysledku
  • RIV/00216208:11130/13:10209630
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • Atorvastatin pretreatment; Statin; Periprocedural myocardial infarction; Percutaneous coronary intervention (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • IE - Irsko
http://linked.open...ontrolniKodProRIV
  • [2CABB01CB7BD]
http://linked.open...i/riv/nazevZdroje
  • International Journal of Cardiology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 168
http://linked.open...iv/tvurceVysledku
  • Hájek, Petr
  • Malý, Martin
  • Tomašov, Pavol
  • Veselka, Josef
  • Zemánek, David
  • Tesař, David
  • Branny, Marian
  • Martinkovicova, Lucie
http://linked.open...ain/vavai/riv/wos
  • 000326184400124
issn
  • 0167-5273
number of pages
http://bibframe.org/vocab/doi
  • 10.1016/j.ijcard.2013.03.002
http://localhost/t...ganizacniJednotka
  • 11130
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 48 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software